AnodyneWiki

Tapentadol

Tapentadol
Tapentadol
Salts
[]
Tapentadol tartrate
Tapentadol tartrate
Tapentadol maleate
Tapentadol maleate
Tapentadol phosphate
Tapentadol phosphate
Tapentadol hydrochloride
Tapentadol hydrochloride
Tapentadol hydrobromide
Tapentadol hydrobromide
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass221.34 g/mol [1]
Melting point202-205 [1]
Predicted LogP3.5 [1]
Structural Identifiers
[]
Molecular formulaC14H23NO
IUPAC name3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol
SMILESCC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C
InChIInChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1
InChIKeyKWTWDQCKEHXFFR-SMDDNHRTSA-N
CAS number175591-23-8
UNIIH8A007M585
PubChem CID9838022
Pharmacokinetics[]
Onset~30 minutes
Elimination half-life4 hours
Duration of action4-6 hours
MetabolismHepatic (mostly via glucuronidation but also by CYP2C9, CYP2C19, CYP2D6)
ExcretionUrine and faeces (1%)
Routes of administrationBy mouth
Dependence liabilityHigh[3]
Addiction liabilityHigh[4]
Toxicity
[]
Rat:
- iv: 40 mg/kg
 [1]

Tapentadol (also known as Cg5503, Bn 200 (base), Cg5503 (base), Bn 200, Bn-200, Cg-5503, Cg5503 ir, 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol, Cg 5503 or phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-) is a substance of the phenylpropylamine class.

Chemistry

Salts []

Tapentadol is typically found in the form of its tartrate, maleate, phosphate, hydrochloride and hydrobromide salts.

 []

Tapentadol is a single defined stereoisomer (optical activity ( - )).

Tapentadol matches Lipinski's rule of five.

There are currently 5 reagent-interactions on

ReagentColor changeDescription
Marquismagenta - reddish purple
Meckelight purple
Mandelinblue-gray (greenish)
Liebermannreddish brown
Froehdeblue

Pharmacology

Mechanism of action []

Tapentadol is a centrally-acting synthetic analgesic. Although their clinical relevance is unclear, tapentadol is believed to have two main mechanisms of action. Tapentadol is a selective mu-opioid receptor (MOR) agonist: it binds to MOR with an affinity greater than or equal to ten-fold affinity compared to delta- and kappa-opioid receptors. Tapentadol also inhibits noradrenaline reuptake, thereby increasing noradrenaline levels and activating alpha-2 receptors to promote analgesia. Tapentadol is a weak serotonin reuptake inhibitor; however, this action does not contribute to its analgesic effect. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target10 (1 contraindicated)

Medical side effects []

119 side effects listed on drug labels in (tapentadol).

  • Nausea
  • Dizziness
  • Syncope
  • Somnolence
  • Constipation
  • Vomiting
  • Asthenia
  • Fatigue
  • Dry mouth
  • Pruritus
  • Insomnia
  • Hyperhidrosis
  • Anxiety
  • Dyspepsia
  • Irritability
  • Lethargy
  • Decreased appetite
  • Pruritus generalised
  • Menopausal symptoms
  • Hot flush
  • Vertigo
  • Arthralgia
  • Musculoskeletal discomfort
  • Confusional state
  • Feeling abnormal
  • Depression
  • Dyspnoea
  • Dermatitis
  • Rash
  • Hypoaesthesia
  • Hypotension
  • Hypotensive
  • Nasopharyngitis
  • Nervousness
  • Tension
  • Tremor
  • Upper respiratory tract infection
  • Urinary tract infection
  • Chills
  • Drug withdrawal syndrome
  • Abdominal discomfort
  • Disturbance in attention
  • Abnormal dreams
  • Erectile dysfunction
  • Vision blurred
  • Feeling hot
  • Anaphylactic shock
  • Angioedema
  • Mental disorder
  • Diarrhoea
  • Gastrointestinal disorder
  • Hallucination
  • Headache
  • Cardiac disorder
  • Immune system disorder
  • Nervous system disorder
  • Palpitations
  • Panic attack
  • Suicidal ideation
  • Ataxia
  • Breast disorder
  • Infection
  • Connective tissue disorder
  • Cough
  • Drug abuse
  • Drug hypersensitivity
  • Dysarthria
  • Osteoarthritis
  • Oedema
  • Eye disorder
  • Hypersensitivity
  • Bundle branch block left
  • Lung disorder
  • Mediastinal disorder
  • Nightmare
  • Paraesthesia
  • Convulsion
  • Withdrawal syndrome
  • Shock
  • Loss of consciousness
  • Tachycardia
  • Pollakiuria
  • Urethral disorder
  • Urinary tract disorder
  • Urticaria
  • Angiopathy
  • Weight decreased
  • Agitation
  • Depressed level of consciousness
  • Gamma-glutamyltransferase increased
  • Aspartate aminotransferase increased
  • Alanine aminotransferase increased
  • Urinary hesitation
  • Malnutrition
  • Skin disorder
  • Disorientation
  • Thinking abnormal
  • Mental disability
  • Illusion
  • Memory impairment
  • Respiratory depression
  • Pulmonary function test decreased
  • Muscle contractions involuntary
  • Euphoric mood
  • Bradycardia
  • Coordination abnormal
  • Impaired gastric emptying
  • Feeling drunk
  • Visual impairment
  • Altered state of consciousness
  • Sexual dysfunction
  • Balance disorder
  • Sensation of heaviness
  • Drug interaction
  • Serotonin syndrome
  • Presyncope
  • Oxygen saturation decreased
  • Infestation
  • Mental retardation

Indications

  • Acute pain
  • Chronic pain
  • Diabetic peripheral neuropathy
  • Low back pain
  • Neuralgia
  • Osteoarthritis
  • Pain
  • Postoperative pain

Subjective effects []

bonzi / Tapentadol []
Routes:
  • Oral (50mg)
nervewing / Tapentadol []
x86pup / Tapentadol []
Routes:
  • Oral

Experience reports

Erowid

There are currently 28 experience reports involving tapentadol on : []

Reddit

There are currently 1 trip reports involving tapentadol on : []

 []

  • Australia: Tapentadol is a Schedule 8.
  • Brazil: Tapentadol is a A1.[5]
  • Canada: Tapentadol is a Schedule I.
  • Germany: Tapentadol is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
  • United Kingdom: Tapentadol is a Class A (Schedule 2 CD) under the "Misuse of Drugs Act 1971".
  • United States: Tapentadol is a Schedule II under the "Controlled Substances Act".[6]
  • European Union: Tapentadol is Prescription only.[7]
  • United Nations: Tapentadol is Unscheduled.
  • Other: Tapentadol is a SE: Förteckning II, In general: ℞ (Prescription only).[8]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 9838022, Tapentadol. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/9838022
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Tapentadol. UNII: H8A007M585. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/H8A007M585
  3. Tapentadol (Monograph). American Society of Health-System Pharmacists (AHFS). 19 April 2023. https://www.drugs.com/monograph/tapentadol.html
  4. Tapentadol Consumer Medicine Information. NPS MedicineWise. September 2020. https://www.nps.org.au/medicine-finder/palexia-ir-immediate-release-tablets
  5. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  6. Tapentadol. MedLine Plus. 2024-03-15. https://medlineplus.gov/druginfo/meds/a610006.html
  7. Active substance(s): tapentadol. List of nationally authorised medicinal products. 21 July 2022. https://www.ema.europa.eu/documents/psusa/tapentadol-list-nationally-authorised-medicinal-products-psusa/00002849/202111_en.pdf
  8. Palexia®, Filmdragerad tablett 50 mg. FASS.se. 3 November 2025. https://fass.se/health/product/20090507000010/fass-text

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 19:00:39
drugsprook2026-11-20 19:00:35
erowidok2026-11-20 19:00:37
gsrsok2026-11-20 19:00:40
hmdbmissing (no HMDB id)2026-11-20 19:00:35
keggok2026-11-20 19:00:37
pubchemok2026-11-20 19:00:35
redditok2026-11-20 19:00:35
siderok2026-11-20 19:00:35
structureok2026-11-20 19:00:35
wikipediaok2026-11-20 19:00:36